Therapeutics

Bicycle Therapeutics Sees Hammer Chart Pattern: Time to Buy? – April 8, 2020

Bicycle Therapeutics plc (BCYC Free Report)  has been struggling lately, but the selling pressure may be coming to an end soon. That is because BCYC recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.

What is a Hammer Chart Pattern?

A hammer chart pattern is a popular technical indicator that is used in candlestick charting. The hammer appears when a stock tumbles during the day, but then finds strength at some point in the session to close near or above its opening price. This forms a candlestick that resembles a hammer, and it can suggest that the market has found a low point in the stock, and that better days are ahead.

Other Factors

Plus, earnings estimates have been rising for this company, even despite the sluggish trading lately. In just the past 60 days alone 3 estimates have gone higher,

Read More

Bicycle Therapeutics Announces Pipeline Progress Update

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced progress updates across its wholly-owned and partnered programs in oncology and non-oncology indications.

“We and our partners have recently achieved important progress in the advancement of our pipeline that we believe could catalyze the next stage of growth for Bicycle,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “Cancer Research UK has identified a recommended dose, which is within the therapeutic range predicted by preclinical models, for the Phase IIa study of BT1718, which we expect to commence this year. Our next-generation Bicycle Toxin Conjugates (BTCs), BT5528 and BT8009, are quickly progressing through respective stages of development. In addition, we believe our recently announced early discovery collaboration with Genentech will allow us to make

Read More

Bicycle Therapeutics partners with Roche

Bicycle Therapeutics, a Cambridge, UK-based biotech, developing proprietary bicyclic peptides has attracted the attention of Roche subsidiary, Genentech. The two companies agreed a collaboration agreement, with Bicycle receiving $30m (€27.4m) in an upfront fee and eligible for a further $1.7bn (€1.55bn) dependent upon milestones met.

The focus will be on the development of small molecules aimed at immuno-oncology (IO) targets. A spokesperson for Bicycle told us that this will allow the company to expand its footprint in the IO space.

When asked in particular what targets would be worked on, the spokesperson only confirmed that they are ‘well-known’ targets that Genentech believes are “particularly well-suited to Bicycle technology.”

Bicyclic peptides are synthetic short peptides constrained to form two loops. According to the company, they combine the pharmacology of a biologic with the pharmacokinetic properties of a small molecule.

In terms of what advantages this may confer, the spokesperson explained

Read More